8-K: Earth Science Tech Reports FY26 Results, Revenue Up 8%

Earth Science Tech, Inc. announced its fiscal year-end financial results for March 31, 2026, reporting an 8% increase in revenue to $35.7 million and a 11% rise in net income to $3.6 million.

Summary

• Earth Science Tech, Inc. reported its financial results for the fiscal year ended March 31, 2026.
• Revenue for the fiscal year increased by 8% to $35.7 million, up from $33.1 million in the prior year.
• Gross profit rose by 5% to $25.5 million, compared to $24.3 million in the previous fiscal year.
• Net income saw an 11% increase, reaching $3.6 million, up from $3.3 million in the prior year.
• Total assets grew by 27% to $9.0 million from $7.1 million at March 31, 2025.
• The company repurchased and retired 4,023,296 shares of common stock during the fiscal year.
• Management highlighted progress in integrating the patient experience across their telemedicine, pharmacy, and fulfillment platform.
• The company also noted continued investment in new products and expansion of its healthcare platform.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report with solid revenue and net income growth, alongside strategic initiatives like share buybacks and platform integration, indicating a company on a growth trajectory.

Positives

• Revenue growth of 8% to $35.7 million for the fiscal year ended March 31, 2026.
• Net income increased by 11% to $3.6 million for the fiscal year ended March 31, 2026.
• Gross profit increased by 5% to $25.5 million for the fiscal year ended March 31, 2026.
• Total assets increased by 27% to $9.0 million as of March 31, 2026.
• Positive operating cash flow generated.
• Strengthened balance sheet without adding debt.
• Repurchased and retired over 7.1 million shares of common stock in fiscal 2026 and subsequent to year-end.
• Continued investment in new products and expansion of the healthcare platform.

Negatives

• Accumulated deficit of $(24,108,199) as of March 31, 2026.
• Unrealized loss on fair value changes of investments of $(957,118) for the year ended March 31, 2026.
• Advertising & marketing expenses significantly increased by over 240% to $2,840,553 from $836,860 in the prior year.

Risks

• Risks and uncertainties that may cause actual results to differ materially from forward-looking statements, including market conditions, costs of goods and services, other expenses, government regulations, litigations, and general business conditions.
• Potential for incorrect underlying assumptions in forward-looking statements.
• The company assumes no obligation to revise or update forward-looking statements except as required by law.

Future Outlook

Management foresees the fiscal year 2026 as laying the essential foundation for the next leg of growth, with this trajectory already showing in fiscal Q1 2027. The company is continuing its aggressive share buyback program, purchasing over 3.1 million shares in the first quarter of fiscal 2027 alone, to create lasting value for shareholders. The upcoming report for the quarter ending June 30, 2026, is expected to demonstrate the progress from the foundation laid in fiscal 2026.

Management Comments

• "Our fiscal 2026 results reflect the meaningful progress we have made over the last several years to build a business that is durable, self-sustaining and positioned for long-term growth."
• "In fiscal 2026, we grew revenue, increased earnings, generated positive operating cash flow and strengthened our balance sheet, all while not adding debt to our balance sheet."
• "These results are driven by the work we have done to better integrate the patient experience across our platform, from telemedicine to pharmacy to fulfillment."
• "By owning more of that process, we serve patients effectively while building a stronger and more profitable business."
• "We delivered these results while remaining disciplined with our capital."
• "We believe we are still in the early stages of what this business can become."
• "Fiscal year-end 2026 laid the essential foundation for what management foresees as our next leg of growth, and this trajectory is already showing in fiscal Q1 2027."
• "By continuing our aggressive share buyback program purchasing over 3.1 million shares in the first quarter of fiscal 2027 alone we are actively creating lasting value for our shareholders."
• "The upcoming report for the quarter ending June 30, 2026, will clearly show how the foundation laid out during fiscal 2026 is transpiring and moving forward."
• "We remain focused on executing the same strategy that has brought us to this point by growing responsibly and investing for the future."

Industry Context

StockSavvy.ai notes that Earth Science Tech's focus on a vertically integrated healthcare platform, combining telemedicine, pharmacy, and fulfillment, aligns with broader industry trends towards patient-centric care and operational efficiency. The company's reported revenue growth and net income increase, alongside a significant share buyback program, suggest a strategy aimed at consolidating market position and enhancing shareholder value within the health and wellness sector.

Stakeholder Impact

• Shareholders: Benefit from increased net income, asset growth, and share repurchases aimed at creating lasting value.
• Patients: Expected to benefit from an integrated patient experience across telemedicine, pharmacy, and fulfillment.
• Employees: May see continued investment in the business and platform expansion.
• Suppliers/Creditors: The company's strengthened balance sheet and debt-free growth strategy may provide stability.

Next Steps

• Reporting on the quarter ending June 30, 2026, to demonstrate continued growth.
• Continuing the aggressive share buyback program.
• Investing in new products and expanding the healthcare platform.
• Focusing on responsible growth and future investment.

Key Dates

Recommendation

While the results show positive growth in revenue and net income, and strategic initiatives like share buybacks are encouraging, the significant increase in advertising and marketing expenses warrants closer monitoring. The company's reliance on forward-looking statements and the presence of an accumulated deficit suggest a need for continued performance validation before a stronger recommendation can be made.

Keywords

Earth Science Tech, ETST, Financial Results, Fiscal Year End, Revenue Growth, Net Income, Healthcare Platform, Share Repurchase